International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials
T. Christopher Mast(United States Military Academy), John W. Shiver(IGM Biosciences (United States)), Lisa Kierstead(United States Military Academy), Paul Coplan(Johnson & Johnson (United States)), Alexander Nikas(United States Military Academy), Esper G. Kallás(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Punee Pitisuttithum(Mahidol Oxford Tropical Medicine Research Unit), Miguel Aste-Amézaga(United States Military Academy), Vladimir Novitsky(Harvard University), Mauro Schechter(Universidade Federal do Rio de Janeiro), Swati B. Gupta(International AIDS Vaccine Initiative), Bernard Mbewe(University of Malawi), Danilo R. Casimiro(Institut Mérieux (France)), Walter L. Straus(United States Military Academy), Nathan Wolfe(Johns Hopkins University), Eftyhia Vardas(University of the Witwatersrand)
Cited by 276
Related Papers
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
|Science|1993|2.3k
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
|Nature|2002|1.2k
Antiretroviral Therapy in Adults
|JAMA|2000|1k
DNA VACCINES
|Annual Review of Immunology|1997|987